OncoLab’s proprietary IP-based platform technology, ANGel, has been recognized for its technological innovation and market potential, earning the company a place among the Top 15 finalists in the 2025 IP-Based Startup Competition hosted by the Korean Intellectual Property Office (KIPO).
Building on this momentum, we will continue to drive the next wave of innovation in cancer immunotherapy by delivering precision medicine solutions through the ANGel platform and expanding our impact in the global biotech market.
Building on this momentum, we will continue to drive the next wave of innovation in cancer immunotherapy by delivering precision medicine solutions through the ANGel platform and expanding our impact in the global biotech market.